Precision oncology care
Dr. Tamrazi is actively collaborating with academic and biotech startups to accelerate the discovery of biomarker-based cancer detection and monitoring platforms.
New FDA-approved test from Travera Inc. predicts an individual patient's response to a cancer drug. Our biopsy center helped to develop and validate this nationally available test.
Travera's unique platform uses extremely small changes in tumor cell mass to identify which drugs a patient might respond to. See example here. This information will help to personalize the treatment for that patient.
Dr. Tamrazi is also guiding another promising collaboration with Travera Inc. for the development of a test to predict response to various immunotherapy options.
More such collaborations are in the works, making the biopsy center an exciting hub for translational clinical research.
